LONDON and CAMBRIDGE, MA--(Marketwire - November 08, 2010) - Cancer drug developer Antisoma
plc (LSE: ASM; USOTC: ATSMY) today announces that the Company's US
Antisoma, Inc., has received a grant of USD 244,000 under the U.S.
Qualifying Therapeutic Discovery Project, a programme created as part of
Patient Protection and Affordable Care Act of 2010. The grant is to support
ongoing development of AS1413 (amonafide L-malate), Antisoma's novel
for acute myeloid leukaemia (AML).
Qualifying Therapeutic Discovery Project grants are awarded to projects
show a reasonable potential to result in new therapies to treat areas of
medical need or prevent, detect or treat chronic or acute diseases and
conditions, reduce the long-term growth of health care costs in the United
States, or significantly advance the goal of curing cancer within 30 years.
Dr Chris Smyth, VP, Clinical Operations at Antisoma, Inc., said: "We are
that the development of AS1413 has qualified for this recognition, and look
forward to reporting the key phase III data on the drug in the near
Except for the historical information presented, certain matters discussed
this statement are forward looking statements that are subject to a number
risks and uncertainties that could cause actual results to differ
from results, performance or achievements expressed or implied by such
statements. These risks and uncertainties may be associated with product
discovery and development, including statements regarding the company's
development programmes, the expected timing of clinical trials and
filings. Such statements are based on management's current expectations,
actual results may differ materially.
Background on Antisoma
Antisoma is a London Stock Exchange-listed biopharmaceutical company that
develops novel products for the treatment of cancer. The Company has
in London, UK and Cambridge, MA. Please visitwww.antisoma.com for further
information about Antisoma.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Antisoma plc via Thomson Reuters ONE